TY - JOUR T1 - Holistic considerations in optimizing a sterile product package to ensure container closure integrity JF - PDA Journal of Pharmaceutical Science and Technology JO - PDA J Pharm Sci Technol DO - 10.5731/pdajpst.2017.007658 SP - pdajpst.2017.007658 AU - Fran L. DeGrazio Y1 - 2017/01/01 UR - http://journal.pda.org/content/early/2017/10/10/pdajpst.2017.007658.abstract N2 - A new major chapter dealing with container closure integrity (CCI) was released by the United States Pharmacopeial Convention (USP). Chapter <1207> provides a significant amount of education and guidance concerning test methodologies to prove that a system is integral and safe for use. The test method used is only one of the major considerations in approaching the challenge of proving an integral system. This paper takes a holistic review of all the major considerations needed in qualifying a new vial system for container closure integrity. There is substantial interplay among many aspects in the process of sealing a vial. This review helps to define major risks that need to be considered and mitigated and reinforces the need to understand the maximum allowable leakage limit (MALL) that is acceptable for a specific drug application. A typical risk-based approach considers materials, test methods, process, people, environment and equipment. Each of these aspects is considered in some detail along with a recommended process flow for building a best practice, science-based approach. This approach will inform decision making for evaluating the correct combination of components and assuring they are assembled and tested in an appropriate manner. This work, once completed, can be the basis for a vial system platform or specific drug application qualification. ER -